IL6 and COVID-19: Furthermore, the surviving and non-surviving severe COVID-19 patients showed significantly increased levels of circulating IL-1α, IL-1β, IL-6, IL-12p40, IL-15 and IL-18 (surviving patients vs. controls: p = 0.017, p = 0.048, p < 0.0001, p = 0.045, p < 0.0001 and p = 0.046, respectively; non-surviving vs. controls: p = 0.005, p = 0.002, p<0.0001, p = 0.049, p < 0.0001 and p = 0.012, respectively) compared to the healthy controls.